Third-generation anti-CD19 CAR T-cells show efficacy without neurotoxicity in B-cell lymphoma phase 1 clinical trial
byMalaghan Institute of Medical ResearchMalaghan Institute GMP lab where CAR T-cells were manufactured for the phase 1 trial. Credit: Malaghan Institute of Medical ResearchThe Malaghan Institute
Updated on: January 26,2024
23
Third-generation anti-CD19 CAR T-cells show efficacy without neurotoxicity in B-cell lymphoma phase 1 clinical trial
byMalaghan Institute of Medical ResearchMalaghan Institute GMP lab where CAR T-cells were manufactured for the phase 1 trial. Credit: Malaghan Institute of Medical ResearchThe Malaghan Institute
Updated on:January 26,2024
23
